Selected research
Industry Research
Drug Safety and Pharmacovigilance Service Industry Research Report 2026
Market perspective
The global Drug Safety and Pharmacovigilance Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Drug Safety and Pharmacovigilance Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drug Safety and Pharmacovigilance Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drug Safety and Pharmacovigilance Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drug Safety and Pharmacovigilance Service include BioPoint, Cmed, Drug Safety Solutions, Hilbrans, Orbis Clinical, Parexel, PharmaLex, ProPharma and SGS, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Drug Safety and Pharmacovigilance Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drug Safety and Pharmacovigilance Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drug Safety and Pharmacovigilance Service Market by Company
BioPoint
Cmed
Drug Safety Solutions
Hilbrans
Orbis Clinical
Parexel
PharmaLex
ProPharma
SGS
SJ Pharma Consulting LLC
Vitrana
X7 Research
Drug Safety and Pharmacovigilance Service Segment by Type
Drug Safety Service
Drug Pharmacovigilance Service
Drug Safety and Pharmacovigilance Service Segment by Application
Experimental Stage
Clinical Stage
Postmarketing Stage
Other
Drug Safety and Pharmacovigilance Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Safety and Pharmacovigilance Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug Safety and Pharmacovigilance Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Safety and Pharmacovigilance Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drug Safety and Pharmacovigilance Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drug Safety Service
- Drug Pharmacovigilance Service
Applications
- Experimental Stage
- Clinical Stage
- Postmarketing Stage
- Other
Companies covered
- BioPoint
- Cmed
- Drug Safety Solutions
- Hilbrans
- Orbis Clinical
- Parexel
- PharmaLex
- ProPharma
- SGS
- SJ Pharma Consulting LLC
- Vitrana
- X7 Research
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drug Safety and Pharmacovigilance Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drug Safety Service
- 2.2.3 Drug Pharmacovigilance Service
- 2.3 Drug Safety and Pharmacovigilance Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Experimental Stage
- 2.3.3 Clinical Stage
- 2.3.4 Postmarketing Stage
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Drug Safety and Pharmacovigilance Service Breakdown Data by Type
- 3.1 Global Drug Safety and Pharmacovigilance Service Historic Market Size by Type (2021-2026)
- 3.2 Global Drug Safety and Pharmacovigilance Service Forecasted Market Size by Type (2027-2032)
4 Drug Safety and Pharmacovigilance Service Breakdown Data by Application
- 4.1 Global Drug Safety and Pharmacovigilance Service Historic Market Size by Application (2021-2026)
- 4.2 Global Drug Safety and Pharmacovigilance Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drug Safety and Pharmacovigilance Service Market Perspective (2021-2032)
- 5.2 Global Drug Safety and Pharmacovigilance Service Growth Trends by Region
- 5.2.1 Global Drug Safety and Pharmacovigilance Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drug Safety and Pharmacovigilance Service Historic Market Size by Region (2021-2026)
- 5.2.3 Drug Safety and Pharmacovigilance Service Forecasted Market Size by Region (2027-2032)
- 5.3 Drug Safety and Pharmacovigilance Service Market Dynamics
- 5.3.1 Drug Safety and Pharmacovigilance Service Industry Trends
- 5.3.2 Drug Safety and Pharmacovigilance Service Market Drivers
- 5.3.3 Drug Safety and Pharmacovigilance Service Market Challenges
- 5.3.4 Drug Safety and Pharmacovigilance Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drug Safety and Pharmacovigilance Service Players by Revenue
- 6.1.1 Global Top Drug Safety and Pharmacovigilance Service Players by Revenue (2021-2026)
- 6.1.2 Global Drug Safety and Pharmacovigilance Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Drug Safety and Pharmacovigilance Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drug Safety and Pharmacovigilance Service Head Office and Area Served
- 6.4 Global Drug Safety and Pharmacovigilance Service Players, Product Type & Application
- 6.5 Global Drug Safety and Pharmacovigilance Service Manufacturers Established Date
- 6.6 Global Drug Safety and Pharmacovigilance Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drug Safety and Pharmacovigilance Service Market Size (2021-2032)
- 7.2 North America Drug Safety and Pharmacovigilance Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drug Safety and Pharmacovigilance Service Market Size by Country (2021-2026)
- 7.4 North America Drug Safety and Pharmacovigilance Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drug Safety and Pharmacovigilance Service Market Size (2021-2032)
- 8.2 Europe Drug Safety and Pharmacovigilance Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drug Safety and Pharmacovigilance Service Market Size by Country (2021-2026)
- 8.4 Europe Drug Safety and Pharmacovigilance Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drug Safety and Pharmacovigilance Service Market Size (2021-2032)
- 9.2 Asia-Pacific Drug Safety and Pharmacovigilance Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drug Safety and Pharmacovigilance Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drug Safety and Pharmacovigilance Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drug Safety and Pharmacovigilance Service Market Size (2021-2032)
- 10.2 South America Drug Safety and Pharmacovigilance Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drug Safety and Pharmacovigilance Service Market Size by Country (2021-2026)
- 10.4 South America Drug Safety and Pharmacovigilance Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drug Safety and Pharmacovigilance Service Market Size (2021-2032)
- 11.2 Middle East & Africa Drug Safety and Pharmacovigilance Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drug Safety and Pharmacovigilance Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drug Safety and Pharmacovigilance Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 BioPoint
- 12.1.1 BioPoint Company Information
- 12.1.2 BioPoint Business Overview
- 12.1.3 BioPoint Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.1.4 BioPoint Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.1.5 BioPoint Recent Developments
- 12.2 Cmed
- 12.2.1 Cmed Company Information
- 12.2.2 Cmed Business Overview
- 12.2.3 Cmed Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.2.4 Cmed Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.2.5 Cmed Recent Developments
- 12.3 Drug Safety Solutions
- 12.3.1 Drug Safety Solutions Company Information
- 12.3.2 Drug Safety Solutions Business Overview
- 12.3.3 Drug Safety Solutions Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.3.4 Drug Safety Solutions Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.3.5 Drug Safety Solutions Recent Developments
- 12.4 Hilbrans
- 12.4.1 Hilbrans Company Information
- 12.4.2 Hilbrans Business Overview
- 12.4.3 Hilbrans Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.4.4 Hilbrans Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.4.5 Hilbrans Recent Developments
- 12.5 Orbis Clinical
- 12.5.1 Orbis Clinical Company Information
- 12.5.2 Orbis Clinical Business Overview
- 12.5.3 Orbis Clinical Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.5.4 Orbis Clinical Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.5.5 Orbis Clinical Recent Developments
- 12.6 Parexel
- 12.6.1 Parexel Company Information
- 12.6.2 Parexel Business Overview
- 12.6.3 Parexel Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.6.4 Parexel Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.6.5 Parexel Recent Developments
- 12.7 PharmaLex
- 12.7.1 PharmaLex Company Information
- 12.7.2 PharmaLex Business Overview
- 12.7.3 PharmaLex Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.7.4 PharmaLex Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.7.5 PharmaLex Recent Developments
- 12.8 ProPharma
- 12.8.1 ProPharma Company Information
- 12.8.2 ProPharma Business Overview
- 12.8.3 ProPharma Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.8.4 ProPharma Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.8.5 ProPharma Recent Developments
- 12.9 SGS
- 12.9.1 SGS Company Information
- 12.9.2 SGS Business Overview
- 12.9.3 SGS Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.9.4 SGS Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.9.5 SGS Recent Developments
- 12.10 SJ Pharma Consulting LLC
- 12.10.1 SJ Pharma Consulting LLC Company Information
- 12.10.2 SJ Pharma Consulting LLC Business Overview
- 12.10.3 SJ Pharma Consulting LLC Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.10.4 SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.10.5 SJ Pharma Consulting LLC Recent Developments
- 12.11 Vitrana
- 12.11.1 Vitrana Company Information
- 12.11.2 Vitrana Business Overview
- 12.11.3 Vitrana Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.11.4 Vitrana Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.11.5 Vitrana Recent Developments
- 12.12 X7 Research
- 12.12.1 X7 Research Company Information
- 12.12.2 X7 Research Business Overview
- 12.12.3 X7 Research Revenue in Drug Safety and Pharmacovigilance Service Business (2021-2026)
- 12.12.4 X7 Research Drug Safety and Pharmacovigilance Service Product Portfolio
- 12.12.5 X7 Research Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst